As we soon head into the first-quarter financial results reporting period, German family-owned pharma major Boehringer Ingelheim came to the fore, reporting its achievements for 2016. Also in the news were positive late-stage clinical results for Paratek Pharmaceuticals’ omadacycline, Astellas Pharma’s buy of Belgian firm Ogeda, lack of investor excitement despite a US approval for Teva Pharmaceutical Industries Huntington’s drug and questions over Tesaro’s PARP inhibitor.
Is this the turnaround Paratek has been looking for?
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial, noted Chris Lang on 24/7WALLSt. Specifically, the firm reported positive top-line results from a global, pivotal Phase III clinical study comparing its once-daily oral and intravenous, broad spectrum investigational antibiotic, omadacycline, to moxifloxacin in the treatment of patients with community-acquired bacterial pneumonia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze